These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22130801)

  • 21. Hepcidin levels and iron status in beta-thalassemia major patients with hepatitis C virus infection.
    Hendy OM; Allam M; Allam A; Attia MH; El Taher S; Eldin MM; Ali A
    Egypt J Immunol; 2010; 17(2):33-44. PubMed ID: 23082485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major.
    Kattamis A; Papassotiriou I; Palaiologou D; Apostolakou F; Galani A; Ladis V; Sakellaropoulos N; Papanikolaou G
    Haematologica; 2006 Jun; 91(6):809-12. PubMed ID: 16769583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic inflammation up-regulates serum hepcidin in exacerbations and stabile chronic obstructive pulmonary disease.
    Tandara L; Grubisic TZ; Ivan G; Jurisic Z; Tandara M; Gugo K; Mladinov S; Salamunic I
    Clin Biochem; 2015 Dec; 48(18):1252-7. PubMed ID: 26164540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular mechanisms regulating hepcidin revealed by hepcidin disorders.
    Camaschella C; Silvestri L
    ScientificWorldJournal; 2011 Jul; 11():1357-66. PubMed ID: 21789471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis.
    Mastrogiannaki M; Matak P; Mathieu JR; Delga S; Mayeux P; Vaulont S; Peyssonnaux C
    Haematologica; 2012 Jun; 97(6):827-34. PubMed ID: 22207682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early effects of erythropoietin on serum hepcidin and serum iron bioavailability in healthy volunteers.
    Lainé F; Laviolle B; Ropert M; Bouguen G; Morcet J; Hamon C; Massart C; Westermann M; Deugnier Y; Loréal O
    Eur J Appl Physiol; 2012 Apr; 112(4):1391-7. PubMed ID: 21818622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepcidin, a new iron regulatory peptide.
    Nicolas G; Viatte L; Bennoun M; Beaumont C; Kahn A; Vaulont S
    Blood Cells Mol Dis; 2002; 29(3):327-35. PubMed ID: 12547223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepcidin biology and therapeutic applications.
    Nemeth E
    Expert Rev Hematol; 2010 Apr; 3(2):153-5. PubMed ID: 21083458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis.
    Liu Q; Davidoff O; Niss K; Haase VH
    J Clin Invest; 2012 Dec; 122(12):4635-44. PubMed ID: 23114598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transferrin is a major determinant of hepcidin expression in hypotransferrinemic mice.
    Bartnikas TB; Andrews NC; Fleming MD
    Blood; 2011 Jan; 117(2):630-7. PubMed ID: 20956801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary hepcidin in congenital chronic anemias.
    Kearney SL; Nemeth E; Neufeld EJ; Thapa D; Ganz T; Weinstein DA; Cunningham MJ
    Pediatr Blood Cancer; 2007 Jan; 48(1):57-63. PubMed ID: 16220548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin.
    Ashby DR; Gale DP; Busbridge M; Murphy KG; Duncan ND; Cairns TD; Taube DH; Bloom SR; Tam FW; Chapman R; Maxwell PH; Choi P
    Haematologica; 2010 Mar; 95(3):505-8. PubMed ID: 19833632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights.
    Rhodes CJ; Howard LS; Busbridge M; Ashby D; Kondili E; Gibbs JS; Wharton J; Wilkins MR
    J Am Coll Cardiol; 2011 Jul; 58(3):300-9. PubMed ID: 21737024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepcidin expression in patients with acute leukaemia.
    Cheng PP; Sun ZZ; Jiang F; Tang YT; Jiao XY
    Eur J Clin Invest; 2012 May; 42(5):517-25. PubMed ID: 22023453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Characteristics of erythropoiesis regulation in population living at high altitude].
    Makeshova AB; Levina AA; Mamukova IuI; Raimzhanov AR
    Ter Arkh; 2004; 76(11):95-7. PubMed ID: 15658550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.
    Ginzburg Y; Rivella S
    Blood; 2011 Oct; 118(16):4321-30. PubMed ID: 21768301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.
    Gardenghi S; Grady RW; Rivella S
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1089-107. PubMed ID: 21075282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stimulated erythropoiesis with secondary iron loading leads to a decrease in hepcidin despite an increase in bone morphogenetic protein 6 expression.
    Frazer DM; Wilkins SJ; Darshan D; Badrick AC; McLaren GD; Anderson GJ
    Br J Haematol; 2012 Jun; 157(5):615-26. PubMed ID: 22449175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells.
    Tanno T; Porayette P; Sripichai O; Noh SJ; Byrnes C; Bhupatiraju A; Lee YT; Goodnough JB; Harandi O; Ganz T; Paulson RF; Miller JL
    Blood; 2009 Jul; 114(1):181-6. PubMed ID: 19414861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepcidin and iron metabolism disorders in patients with chronic kidney disease.
    Jelić M; Cvetković T; Djordjević V; Damnjanovć G; Vlahović P; Kocić G; Djindjić N; Jovović B; Antić A
    Vojnosanit Pregl; 2013 Apr; 70(4):368-73. PubMed ID: 23700940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.